{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:33:30Z","timestamp":1787690010470,"version":"build-2784847793"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.maturitas.2010.11.003","type":"journal-article","created":{"date-parts":[[2010,12,4]],"date-time":"2010-12-04T04:42:49Z","timestamp":1291437769000},"page":"143-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Management of osteoporosis in men on androgen deprivation therapy"],"prefix":"10.1016","volume":"68","author":[{"given":"Robert A.","family":"Adler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2010.11.003_bib0005","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation therapy for prostate cancer","volume":"352","author":"Shaninian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0010","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/0003-4819-148-9-200805060-00009","article-title":"Screening for osteoporosis in men: a systematic review for an American college of physicians guideline","volume":"148","author":"Liu","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0015","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1210\/jc.2004-0746","article-title":"Vitamin D deficiency and seasonal variation in an adult South Florida population","volume":"90","author":"Levis","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0020","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1210\/jc.2006-2250","article-title":"Low vitamin D status despite abundant sun exposure","volume":"92","author":"Binkley","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4158\/EP.14.1.127","article-title":"Vitamin D status in United States war veterans","volume":"14","author":"Kumari","year":"2008","journal-title":"Endocr Pract"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0030","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00198-010-1285-3","article-title":"IOF position statement: vitamin D recommendations for older adults","volume":"21","author":"Dawson-Hughes","year":"2010","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0035","series-title":"Clinician's guide to prevention and treatment of osteoporosis","author":"National Osteoporosis Foundation","year":"2008"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0040","doi-asserted-by":"crossref","first-page":"c3691","DOI":"10.1136\/bmj.c3691","article-title":"Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis","volume":"341","author":"Bolland","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0045","article-title":"Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RXT and a 4.5-year follow-up","author":"Lewis","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0050","doi-asserted-by":"crossref","first-page":"315","DOI":"10.7326\/0003-4819-152-5-201003020-00010","article-title":"Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events","volume":"152","author":"Wang","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0055","article-title":"Osteoporosis in men: the value of laboratory testing","author":"Ryan","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0060","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00198-009-1105-9","article-title":"Bone mineral density and prevalent osteoarthritis of the hip in older men for the Osteoporosis fractures in men (MrOS) study group","volume":"21","author":"Chaganti","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0065","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jcem.87.8.8782","article-title":"Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs","volume":"87","author":"Mittan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0070","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.urology.2005.07.017","article-title":"Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy","volume":"67","author":"Bruder","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0075","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1210\/jc.2007-1402","article-title":"Approach to the prostate cancer patient with bone disease","volume":"93","author":"Greenspan","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0080","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.bone.2009.01.373","article-title":"FRAX\u00ae and its applications to clinical practice","volume":"44","author":"Kanis","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0085","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/j.juro.2010.02.022","article-title":"Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer","volume":"183","author":"Saylor","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0090","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00198-009-0984-0","article-title":"Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX\u2122","volume":"21","author":"Adler","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0095","article-title":"Prognosis of fracture: evaluation of predictive accuracy of the FRAX\u2122 algorithm and the Garvan nomogram","author":"Sandhu","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0100","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.bone.2003.12.028","article-title":"Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden","volume":"34","author":"Borgstrom","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0105","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0110","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M","article-title":"The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study","volume":"92","author":"Diamond","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0115","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0120","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jocd.2006.07.005","article-title":"Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy","volume":"9","author":"Bruder","year":"2006","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0125","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0130","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0135","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1442-2042.2007.01911.x","article-title":"Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer","volume":"14","author":"Ishizaka","year":"2007","journal-title":"Int J Urol"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0140","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/j.1464-410X.2009.08622.x","article-title":"Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis","volume":"104","author":"Planas j","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0145","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.urology.2009.01.046","article-title":"Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy","volume":"73","author":"Izumi","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0150","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/j.juro.2009.07.046","article-title":"Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy","volume":"182","author":"Bhoopalam","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0155","doi-asserted-by":"crossref","DOI":"10.1111\/j.1464-410X.2010.09329.x","article-title":"Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer","author":"Taxel","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0160","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.urology.2009.11.083","article-title":"The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis","volume":"75","author":"Campbell","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0165","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0170","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00223-010-9364-1","article-title":"Adverse effects of bisphosphonates","volume":"86","author":"Abrahamsen","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0175","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0180","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1210\/jc.2003-032058","article-title":"Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial","volume":"89","author":"Smith","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0185","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.juro.2010.06.022","article-title":"Toremifene to reduce fracture irsk in men receiving androgen deprivation therapy for prostate cancer","volume":"184","author":"Smith","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0190","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0195","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.maturitas.2010.05.009","article-title":"SERMs: progress and future perspectives","volume":"67","author":"Pickar","year":"2010","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0200","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2010.11.003_bib0205","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00198-007-0550-6","article-title":"Cost-effective osteoporosis treatment thresholds: the United States perspective","volume":"19","author":"Tosteson","year":"2008","journal-title":"Osteoporos Int"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512210004147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512210004147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:51:39Z","timestamp":1759913499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512210004147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0378512210004147"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2010.11.003","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of osteoporosis in men on androgen deprivation therapy","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2010.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}